Moreover, chemotherapy seemed to negatively influence LRIG2 expression in both, secondary and primary GBM, as less LRIG2 was measured in patients treated with temozolomide (primary GBMs: 0.103 ± 0.097 vs. 0.529 ± 0.416; n.s.; Figure 5B, 5E; secondary GBMs: 0.697 ± 0.270 vs. 0.995 ± 0.259; n.s.; Figures 5C, 5F and 6C, 6D). Here, LRIG2 is linked to glioblastoma.